Virtual Event
Gene Agnostic Therapies
VirtualOver the past few years we have talked a lot about the promise of gene therapy – treatments designed for a specific gene, like Luxturna for RPE56. There is growing …
Over the past few years we have talked a lot about the promise of gene therapy – treatments designed for a specific gene, like Luxturna for RPE56. There is growing …
Discover 5 EQ-based strategies for managing an anxious or emotionally elevated child during optometry pre-testing in 2026. Learn how to de-escalate and ensure accurate clinical data.
Learn MoreNow available in Canada, Dilli Dalli offers fit-focused eyewear for infants, toddlers and children, with SoftTouch, TR-90 and lightweight metal options designed to support pediatric dispensing.
Read moreAYA Optical brings together Indigenous art and contemporary eyewear design, creating frames that honour artists while offering a distinctive and meaningful visual identity.
Read moreThe Vision Council Foundation has expanded its See What Matters initiative with new back to school toolkits focused on childhood myopia, digital eye strain and the importance of annual eye exams.
Read moreBausch + Lomb is advancing two first in class therapies following new clinical results, including a Phase 3 dry eye combination treatment and a TRPV1 antagonist showing early pain reduction.
Read more
Discover 5 EQ-based strategies for managing an anxious or emotionally elevated child during optometry pre-testing in 2026. Learn how to de-escalate and ensure accurate clinical data.
Learn MoreNow available in Canada, Dilli Dalli offers fit-focused eyewear for infants, toddlers and children, with SoftTouch, TR-90 and lightweight metal options designed to support pediatric dispensing.
Read MoreAYA Optical brings together Indigenous art and contemporary eyewear design, creating frames that honour artists while offering a distinctive and meaningful visual identity.
Read MoreThe Vision Council Foundation has expanded its See What Matters initiative with new back to school toolkits focused on childhood myopia, digital eye strain and the importance of annual eye exams.
Read MoreBausch + Lomb is advancing two first in class therapies following new clinical results, including a Phase 3 dry eye combination treatment and a TRPV1 antagonist showing early pain reduction.
Read More
Discover 5 EQ-based strategies for managing an anxious or emotionally elevated child during optometry pre-testing in 2026. Learn how to de-escalate and ensure accurate clinical data.
Learn MoreNow available in Canada, Dilli Dalli offers fit-focused eyewear for infants, toddlers and children, with SoftTouch, TR-90 and lightweight metal options designed to support pediatric dispensing.
Read moreAYA Optical brings together Indigenous art and contemporary eyewear design, creating frames that honour artists while offering a distinctive and meaningful visual identity.
Read moreThe Vision Council Foundation has expanded its See What Matters initiative with new back to school toolkits focused on childhood myopia, digital eye strain and the importance of annual eye exams.
Read moreBausch + Lomb is advancing two first in class therapies following new clinical results, including a Phase 3 dry eye combination treatment and a TRPV1 antagonist showing early pain reduction.
Read more
Discover 5 EQ-based strategies for managing an anxious or emotionally elevated child during optometry pre-testing in 2026. Learn how to de-escalate and ensure accurate clinical data.
Learn MoreNow available in Canada, Dilli Dalli offers fit-focused eyewear for infants, toddlers and children, with SoftTouch, TR-90 and lightweight metal options designed to support pediatric dispensing.
Read moreAYA Optical brings together Indigenous art and contemporary eyewear design, creating frames that honour artists while offering a distinctive and meaningful visual identity.
Read moreThe Vision Council Foundation has expanded its See What Matters initiative with new back to school toolkits focused on childhood myopia, digital eye strain and the importance of annual eye exams.
Read moreBausch + Lomb is advancing two first in class therapies following new clinical results, including a Phase 3 dry eye combination treatment and a TRPV1 antagonist showing early pain reduction.
Read more